In a single-arm trial in non-ambulatory patients with Duchenne muscular dystrophy, patients treated with anti-CCN2 therapy had lower biceps brachii muscle fibrosis scores and improved upper limb function and grip strength compared to historic controls [29]. Here, CCN2 is linked to Duchenne muscular dystrophy.